Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b744d7e837861ddb5d6002fa021c22b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e713112ef6ed1706e9703b76ce3ca020 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-01 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-05 |
filingDate |
2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_355b78377629f6d3bb31cf96ea06765e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58cdcd7a5d832daaa4433719799fa2f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f80706007c0f04639e779d8b81985af3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e5df8322d3bb1790a4c41664a422953 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcdd0010cbd0b63624c5c0c718f9b794 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27d33f13f76b7199ac70e2cb8a129905 |
publicationDate |
2021-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2021165290-A |
titleOfInvention |
Compositions for the prevention and / or treatment of pathological conditions associated with α-glucosidase |
abstract |
PROBLEM TO BE SOLVED: To provide a hypoglycemic molecule for treating and / or preventing type 2 diabetes, which has fewer side effects than existing treatments. SOLUTION: The composition comprises at least one XAP peptide for inhibiting α-glucosidase (where X represents amino acid-free or valine). [Selection diagram] None |
priorityDate |
2014-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |